FDA recently cleared a software upgrade to Hyperfine’s portable MRI device that enables scenes in under 3 minutes with no ionizing radiation, the Austin, Texas–based company said today. Hyperfine officials think the advancement could significantly improve the monitoring of hydrocephalus — brain fluid build-up — in children. Pediatric patients may have trouble staying still for […]
Neurological
Welcome to MassDevice's Neurological Hub, your resource for the latest news in the neurological device space. Stay informed about the innovations and business news shaping the neurological industry.
🧠 Narrow your focus with these categories:
Neuromodulation/Neurostimulation | Bioelectronic Medicine | Pain Management | Brain-Computer Interfaces
Here are the top neurological device features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ 7 brain-computer interface companies you need to know
+ Brain breakthroughs: Aprinoia Therapeutics’ harnesses AI and strategic partnerships to propel neurodegenerative disease research
+ Natalizumab and PML: The complex dance of benefit and risk for MS
Latest Neurological News
CVRx launches new Barostim programmer in U.S.
CVRx (Nasdaq:CVRX) announced that it launched its new Barostim programmer following its approval by the FDA earlier this year. Minneapolis-based CVRx designed its second-generation programmer to operate on an upgraded cellular network to enable remote view access. It also includes an improved user interface that simplifies implantable pulse generator (IPG) programming. According to a news […]
Abbott wins breakthrough nod for deep brain stimulation for managing severe depression
Abbott (NYSE:ABT) announced today that it received FDA breakthrough device designation for its deep brain stimulation (DBS) system. The breakthrough nod allows Abbott to investigate the use of its DBS system in treatment-resistant depression (TRD), a form of major depressive disorder (MDD). Abbott Park, Illinois-based Abbott designed its DBS system as a personalized, adjustable therapy […]
Orchestra BioMed to go public, partner with Medtronic on cardiac neuromodulation therapy
Orchestra BioMed today announced a slew of agreements, including a strategic collaboration with Medtronic (NYSE:MDT) and a SPAC deal to take the company public. The global strategic collaboration will progress the development of Orchestra BioMed’s BackBeat Cardiac Neuromodulation Therapy (CNT) as a potential treatment for hypertension in patients indicated for a cardiac pacemaker. Additionally, Orchestra […]
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt Lake […]
SpineX enrolls first patient in spinal neuromodulation technology trial
SpineX announced today that it enrolled the first patient in its pivotal trial evaluating the Scone neuromodulation device. Los Angeles-based SpineX will evaluate the safety and effectiveness of the non-invasive spinal neuromodulation technology for the treatment of neurogenic bladder. The first patient was enrolled at the Rancho Research Institute of the Rancho Los Amigos National […]
FDA grants breakthrough nod for Carthera’s SonoCloud-9
Carthera announced today that it received FDA breakthrough device designation for its SonoCloud-9 system. Paris-based Carthera designed SonoCloud-9 for implantation in a skull window below the skin. Once in place, the device becomes invisible. When activated for a few minutes using a transdermal needle connected to an external control unit, it uses low-intensity pulsed ultrasound […]
Data backs Pear Therapeutics digital therapeutic for opioid use disorder
Pear Therapeutics (Nasdaq:PEAR) today shared real-world data highlighting low costs with its reSET-O prescription digital therapeutic (PDT). Boston-based Pear Therapeutics’ reSET-O represents the only FDA-authorized PDT for the treatment of opioid use disorder (OUD). Get the full story at our sister site, Drug Delivery Business News.
FDA clears Ekso Bionics’ robotic exoskeleton for use with MS patients
Ekso Bionics (Nasdaq:EKSO) announced today that it received FDA 510(k) clearance for its EksoNR robotic exoskeleton. Richmond, California–based Ekso Bionics designed the EksoNR technology for use with Multiple Sclerosis (MS) patients. According to a news release, EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use in patients with MS, significantly expanding […]
Pear Therapeutics reports positive real-world data for chronic insomnia treatment
Pear Therapeutics (Nasdaq:PEAR) today announced real-world data from a trial of its Somryst prescription digital therapeutic (PDT). Data showed that Somryst, the only FDA-authorized PDT for treating chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity both immediately following treatment and at six-months follow-up. Get the full story at our sister site, […]
Digital therapeutics developer Better Therapeutics names new CEO
Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Frank Karbe as its new president and CEO. San Francisco-based Better Therapeutics develops prescription digital therapeutics (PDTs) based on nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases. Get the full story at our sister site, Drug Delivery Business News.